Skip to main content
. 2022 Sep;15(9):1563–1574. doi: 10.1016/j.jcmg.2021.11.027

Table 1.

Baseline Characteristics, Cardiovascular Risk Factors, and CMR Biomarkers

All Patients MACE (n = 73) No MACE (n = 948) AUCk P Value HR (95% CI) HR P Value
Age, y 63 (52 to 72) 72 (61 to 77) 63 (52 to 72) 0.659 <0.001 1.80 (1.39-2.32) <0.001
Sex 753/1,011 (74.5) 46/71 (64.8) 707/940 (75.2) 0.505 0.052 0.81 (0.65-1.00) 0.050
Height, cm 2 (1 to 2) 2 (1 to 3) 1 (1 to 2) 0.597 0.003 0.69 (0.55-0.86) 0.001
Weight, kg 81 (72 to 90) 76 (70 to 86) 82 (73 to 90) 0.568 0.035 0.82 (0.64-1.05) 0.110
Cardiovascular risk factors
 Current smoking 405/935 (43.3) 19/63 (30.2) 386/872 (44.3) 0.522 0.029 0.75 (0.57-0.97) 0.032
 Hypertension 716/1,010 (70.9) 61/71 (85.9) 655/939 (69.8) 0.545 0.004 1.53 (1.13-2.08) 0.006
 Hyperlipoproteinemia 624/1,005 (62.1) 45/71 (63.4) 579/934 (62.0) <0.5 0.816 1.03 (0.81-1.30) 0.824
 Diabetes mellitus 231/1,010 (22.9) 26/71 (36.6) 205/939 (21.8) 0.526 0.004 1.34 (1.09-1.64) 0.005
 Body mass index, kg/m2 27.4 (25.0 to 30.4) 27.0 (25.2 to 30.8) 27.4 (25.0 to 30.3) <0.5 0.959 1.03 (0.82-1.30) 0.773
 Body surface area, m2 1.95 (1.83 to 2.08) 1.88 (1.76 to 2.00) 1.96 (1.83 to 2.08) 0.593 0.006 0.74 (0.59-0.94) 0.014
Killip class on admission 0.573 <0.001 0.52 (0.41-0.65) <0.001
 1 899/1,011 (88.9) 49/71 (69.0) 850/940 (90.4)
 2 76/1,011 (7.5) 13/71 (18.3) 63/940 (6.7)
 3 20/1,011 (2.0) 4/71 (5.6) 16/940 (1.7)
 4 16/1,011 (1.6) 5/71 (7.0) 11/940 (1.2)
No. of diseased vessels 0.567 0.003 1.40 (1.12-1.75) 0.003
 1 502/1,011 (49.7) 25/71 (35.2) 477/940 (50.7)
 2 310/1,011 (30.7) 23/71 (32.4) 287/940 (30.5)
 3 199/1,011 (19.7) 23/71 (32.4) 176/940 (18.7)
TIMI flow grade after PCI <0.5 0.318 0.95 (0.77-1.16) 0.598
 0 19/1,011 (1.9) 1/71 (1.4) 18/940 (1.9)
 1 21/1,011 (2.1) 2/71 (2.8) 19/940 (2.0)
 2 78/1,011 (7.7) 8/71 (11.3) 70/940 (7.4)
 3 893/1,011 (88.3) 60/71 (84.5) 833/940 (88.6)
CMR biomarkers
 LV ESV, mL 70 (53 to 91) 86 (60 to 110) 69 (53 to 90) 0.599 0.004 1.43 (1.18-1.73) <0.001
 LV EDV, mL 144 (117 to 171) 145 (121 to 170) 144 (117 to 172) <0.5 0.987 1.05 (0.83-1.33) 0.679
 LVEF, % 50.5 (43.3 to 57.3) 40.6 (33.1 to 52.2) 50.8 (44.0 to 57.5) 0.683 <0.001 0.80 (0.74-0.87) <0.001
 Infarct size, mL 17.2 (6.4 to 30.2) 24.6 (9.7 to 36.4) 16.7 (6.0 to 29.9) 0.591 0.006 1.29 (1.08-1.53) 0.005
 Infarct size (% LV mass) 13.4 (5.4 to 21.8) 20.3 (9.6 to 28.9) 13.1 (5.3 to 21.4) 0.609 0.001 1.44 (1.18-1.76) <0.001
 MVO, mL 0.00 (0.00 to 1.90) 0.40 (0.00 to 3.00) 0.00 (0.00 to 1.80) 0.543 0.060 1.27 (1.11-1.45) <0.001
 MVO (% LV mass) 0.00 (0.00 to 1.39) 0.32 (0.00 to 2.15) 0.00 (0.00 to 1.27) 0.547 0.044 1.26 (1.09-1.46) 0.002
ES shape 0.680
 Mode 1 −5 (−135 to 126) 62 (−61 to 233) −10 (−136 to 119) 0.002 1.49 (1.18-1.87) <0.001
 Mode 5 0 (−34 to 36) −11 (−51 to 22) 1 (−33 to 37) 0.014 0.73 (0.58-0.91) 0.006
 Mode 6 −3 (−30 to 28) −21 (−44 to 3) −2 (−29 to 30) <0.001 0.64 (0.50-0.81) <0.001
Contraction displacement 0.716
 Mode 3 −4 (−54 to 62) 49 (−29 to 106) −6 (−55 to 59) <0.001 1.70 (1.36-2.12) <0.001
 Mode 5 3 (−37 to 39) −30 (−57 to 23) 4 (−33 to 40) <0.001 0.63 (0.51-0.78) <0.001
 Mode 16 1 (−15 to 14) −9 (−19 to 5) 1 (−14 to 15) <0.001 0.65 (0.52-0.82) <0.001

Values are median (IQR) or n/N (%). P values calculated between MACE and No MACE groups. HRs presented with 95% CIs and predictor significance. AUCk provides the predictive power of each biomarker, assessed via linear discriminant analysis (median AUC, 10-cross-fold validated, 100 random data splits).

AUC = area under the receiver-operating characteristic curve; CMR = cardiac magnetic resonance; EDV = end-diastolic volume; ESV = end-systolic volume; LV = left ventricular; LVEF = left ventricular ejection fraction; MACE = major adverse cardiac events; MVO = microvascular obstruction; PCI = percutaneous coronary intervention; TIMI = Thrombolysis in Myocardial Infarction.